Regulatory Pfizer, Arvinas join SERD club with Veppanu approval PharmaphorumArvinas and Pfizer's Veppanu is the first PROTAC - and third oral SERD for breast cancer - to be approved by the FDA.OncologyRead full story pharminent May 4, 2026 (Last updated: May 4, 2026) Pharmaphorum Arvinas and Pfizer’s Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA. Oncology Read full story Post navigation Previous: Novartis unveils North Carolina API plant as final piece of $23B US expansionNext: Novo Nordisk to launch Ozempic for type 2 diabetes in US Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
